From molecular
complexity
to clear decisions

test

THE MOST INNOVATIVE WAY FOR CANCER INTERPRETATION

header-img
Image
Image
Image
Image
Image

PLATFORM TOO COMPLICATED?

NOT TRUSTING THE INTERPRETATION REPORTING?

RARE CANCER TYPES AND NEW VARIANTS INTERPRETATION?

WASTING TOO MUCH TIME IN BIBLIOGRAPHY SEARCH?

DATA NOT CENTRALIZED IN A UNIQUE PLACE?

REPORT NOT SUITED TO YOUR NEEDS?

Are you facing one of these issues with your NGS DATA interpretation platform?

OncoKDM is a web-based platform that turns your raw data into actionable clinical insight. OncoKDM is a powerful tool that addresses NGS, IHC, MSI and TMB data to provide up-to-date and accurate interpretation.

The comprehensive and interactive report includes quality control data, patient clinical data, in-depth NGS variants annotation, treatments and clinical trials options.

Resolve this now

OncoKDM for BioInformaticians

Today, we are facing data challenges finding clinically actionable insights necessary to generate treatments hypotheses and classify patient risk. The working bioinformatician has had contend with a multitude of database alignment formats, both in text or binary, for several years to call and sort variants. OncoKDM platform and its biologist's team are your key partners to ease your variant calling and interpretation work. Referencing it with complete and up to date variants, drug, and clinical trials databases.

OncoKDM for Oncologists

As you know combining different molecular profiling assays with clinical data is the key to select the best options and maximising the clinical benefit of the treatment. OncoDNA can combine all these informations in its powerful platform OncoKDM. Pathologists and BioIT can upload all their molecular data in OncoKDM for variant calling and interpretation and generate the type of report you need, with all the mutations, IHC markers, TMB and MSI.  OncoKDM provides you also the best available drug choices but also the clinical trials linked with your patient results.

OncoKDM for Pathologists

Molecular profiling has become a method of choice for detection of somatic variants and was rapidly adopted by clinical laboratories. However, this new method is challenging and requires regular scientific updates. The difficulties are to identify actionable markers or variants linked with approval drug or therapies under development in clinical trials. OncoKDM provides the pathologist with the most comprehensive interpretation combination of various molecular profiling (IHC, NGS, MSI, FISH…).

How does it work?

OncoKDM provides you with up-to-date interpretation of your NGS oncology data. You simply need to upload your FASTQ, BAM or VCF fils on our platform in a fewx clicks.

Image

UPLOAD DATA

Add your data in a few clicks and choose your favorite technology

Image

RUN TEMPLATE

Create several samples based on the same technologies and parameters

Image

ADD PATIENT CASE

Create a patient case from your uploaded data and fill in with information

Interactive report with insightful widgets

Medical Information

Patient-centric, OncoKDM platform gathers mandatory data such as medical information and patient history.

Quality Control

  • Quality control of your data including read length distribution and uniformity assessment

Next Generation Sequencing

  • Next-Generation Sequencing panel encompasses  smart variant classification including biological and therapeutical impacts, CNV analysis, the list of genes covered and finally the coverage and the uniformity quality control to the exon level

Drugs recommendations

  • Drug regimen recommended or to avoid based on official guidelines and referenced clinical evidences

Additional Tests

  • Beyond the usual suspects. Learn more from data by including additional tests as Immunohistochemistry, translocations, unusual splicing or methylation or add a extra layer of interpretation on top of NGS data.

Immunogram, for immunotherapy prediction

  • The immunogram shows the potential response to immunotherapy. It is created by (1) the percentage of PD-L1 positive tumor cells, (2) the percentage of infiltrated CD8+ T cells, (3) the level of tumor mutational burden, (4) the micro satellite stability status of the tumor (5) the presence of mutations associated with either sensitivity or resistance to immunotherapy. The larger the area, the better the patient should answer to immunotherapy.

Clinical Trials

  • Worldwide active clinical trials list based on patient specific condition and molecular profile

Comprehensive Summary

The comprehensive summary reports all conclusions  including the key findings, a simplified pathway analysis and the treatment recommendations based on molecular and clinical evidence.

Bibliography

List of scientific papers that have been used to build up the  personalised report.

Illumina

AmpliSeq for Illumina BRCA Panel, AmpliSeq for Illumina Cancer Hotspot Panel V2, AmpliSeq for Illumina Comprehensive Panel V3, AmpliSeq for Illumina Focus Panel, TruSight Tumor 170, TruSight Tumor 15, TruSight Oncology 500

Agilent

ClearSeq Comprehensive Cancer Panel

Qiagen

Human Breast cancer Panel, Human Colorectal cancer Panel, Human Lung cancer Panel, Human Actionable Solid Tumor Panel, Human BRCA1 & 2 Panel Human BRCA1 & 2 Plus Panel

OncoKDM is technology-agnostic

Ion Torrent

OncoMINE Focus Assay, OncoMINE Comprehensive Assay, OncoMINE BRCA Assay

Archer DX

Any panel starting from the VCF files

What if my technology is not on the list?

Challenge us
Image

A customizable interface suited to your branding

Want to make OncoKDM a fully integrated tool? Change the colors add your logo and make it personalised and tailored to your brand. Once done both interface and generated reports will be customized to your brand!

A user-friendly platform

You remain the owner of the final report. Every information on which our biological and clinical interpretations are based is referenced in the report. Therefore, all data can be verified and edited to suit your needs or guidelines. You will always have the last word on the final report you want to share. Through the editing feature, you are able to modify the variant classification, the summary, the drugs choices, the clinical trials list and more, prior to your validation. The report can also be easily shared with your colleagues, following first validation by an in-house trained PhD.

Medical information

Customisable clinical form Sequencing-related information Possibility to include pathology information such as H&E staining tumour sample slide

Quality Control

Quality control of your data including read length distribution and uniformity assessment

Next Generation Sequencing

Smart variant classification including biological and therapeutical impacts (CNV, list of genes, coverage, MSI, TMB,...)

Bibliography

List of scientific papers that have been used to build up the report

Watch me if you can

Discover how OncoKDM provides daily support to oncologists and laboratory heads

Choose your formula

OncoKDM is available in 3 formulas according to your needs? Click on the most suited for you to get a personalised quotation

STANDARD


Address the needs
of most laboratories

Key points:
DNA
VCF
NGS
Hotspots
Interpretation


Discover

PREMIUM


Go beyond
the usual
interpretation

Key points:
DNA
RNA
Fastq or BAM
NGS, MSI, TMB, LOH, CNV
IHC Interpretation Quality Controls


Discover

CUSTOM


Provide best
in class reports

Tailored
to your projects


Discover

Frequently Asked Questions

OncoKDM can analyze NGS data from any DNA panel or RNA Fusion (targeted) experiment and calculate MSI (Micro Satellite Instability), TMB (Tumor Mutational Burden), LOH (Loss of Heterozygozity), loss of copy, tumor-normal analysis…Note we do not currently analyze RNA-Seq differential expression, RNA data from Ion Torrent, whole transcriptome data, or germline mutation.

We are compliant with ISO 27001:2013 (information security management systems) and ISO 13485:2016 (medical devices quality management). We are GDPR compliant. We are GCP compliant

Read length, read quality, coverage, sequencing bias, exon and/or gene mapping are all used as part our QC process.

No, OncoKDM is a somatic dedicated interpretation platform

The knowledge database was generated by manually reviewing public information/scientific publications (PubMED). Our team of scientists interprets and extracts relevant information used to populate our database.Note : We don’t necessarily track the database version (i.e COSMIC v83), or utilize database that have subscription fee for commercial usage.
Image

Testimonials

testimonial

Given the expertise of OncoDNA delivering solutions in precision medicine, we initiate this collaboration with enthusiasm to produce a specific SOLTI OncoKDM solution which will integrate the current and future molecular data types that might reveal unappreciated vulnerabilities in the tumor of AGATA patients

Dr. Sonia Pernas | Institut Català d'Oncologia
testimonial

I'm an early user of OncoSHARE, the first reporting system developed by OncoDNA. I like the interpretation system which combines DNA and RNA sequencing, pathology, immunohistochemistries,… Now with OncoKDM, I'm very glad that our laboratory can use it to perform interpretation of our cancer data.

Dr. Philippe Aftimos | Institut Jules Bordet
testimonial

Comparing to competitors, OncoKDM includes patient-centric features enabling pathologists and oncologist to take the right treatment decisions according to the patient data and history. Moreover, OncoKDM is user-friendly and easy to use, one other advantage!

Byung Chul Kim, Ph.D. | CEO of Clinomics Inc.

RELEASE OF NGS FOR ONCOLOGY BAROMETER REPORT!

All the results and analysis gathered in the report will be presented by our scientific group during a WEBINAR session to be held on Tuesday, June 18th, 1 PM CET.

Discover the new interpretation needs and get beyond the variant calling by attending our WEBINAR!


Registration link: https://bit.ly/2HluDNj